Tixagevimab/AZD8895 represents a distinct therapeutic approach utilizing dual monoclonal proteins. Specifically, these compounds function by precisely connecting to the S1 area of the SARS-CoV-2 pathogen, preventing https://bookmarks-hit.com/story101042/tixagevimab-azd8895-a-deep-examination-into-its-mechanism-of-operation